With the continuous growth of the global biotechnology and vaccine industry, more and more companies are joining in. Risk assessment in the field of biopharmaceuticals has drawn the attention of the whole society. There are lots of factors such as market competition, government intervention, cost increases, product safety, and breaking laws and rules, resulting in an increase in the company's financial risk. Facing these challenges, this research is based on overall analysis and searching for company data, by adopting the company's financial risk management calculation method to compare the selected companies, such as market risk-return rate, market risk-free return rate, weighted average capital cost, and so on. This research has found that Pfizer has a higher risk compared to other companies but the challenges and opportunities coexist by raising legal awareness, improving management measures, and other means to reduce risks. Its future development prospects are still considerable. The following is a multidimensional financial risk analysis of Pfizer Company.
Read full abstract